Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Integrative genomic and transcriptomic analyses illuminate the ontology of HER2-low breast carcinomas.

Genome medicine - 29 Aug 2022

Berrino Enrico, Annaratone Laura, Bellomo Sara Erika, Ferrero Giulio, Gagliardi Amedeo, Bragoni Alberto, Grassini Dora, Guarrera Simonetta, Parlato Caterina, Casorzo Laura, Panero Mara, Sarotto Ivana, Giordano Silvia, Cereda Matteo, Montemurro Filippo, Ponzone Riccardo, Crosetto Nicola, Naccarati Alessio, Sapino Anna, Marchiò Caterina

Abstract excerpt

BACKGROUND: The "HER2-low" nomenclature identifies breast carcinomas (BCs) displaying a HER2 score of 1+/2+ in immunohistochemistry and lacking ERBB2 amplification. Whether HER2-low BCs (HLBCs) constitute a distinct entity is debated. METHODS: We performed DNA and RNA high-throughput analysis on 99 HLBC samples (n = 34 cases with HER2 score 1+/HLBC-1, n = 15 cases with HER2 score 2+ and ERBB2 not...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Breast Cancer Treatment Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Breast Neoplasms

Share to Gene Expression Profiling

Share to Genomics

Share to Mutation

Share to Transcriptome

Source

Open in PubMed Open full text

Identifiers

PMID: 36038884
DOI: 10.1186/s13073-022-01104-z
PMCID: PMC9426037

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Integrative genomic and transcriptomic analyses illuminate the ontology of HER2-low breast carcinomas.PMID 36038884Read ↗

Clinical and molecular characteristics of HER2-low triple-negative breast cancer: insights from multi-omics analysisSemantic proximity Read ↗

Human Epidermal Growth Factor Receptor 2 Alterations and Prognostic Implications in All Subtypes of Breast Cancers.Semantic proximity Read ↗

Deciphering HER2 Breast Cancer Disease: Biological and Clinical ImplicationsSemantic proximity Read ↗

Comprehensive genomic characterization of HER2-low and HER2-0 breast cancerSemantic proximity Read ↗

Minireview: Basal-Like Breast Cancer: From Molecular Profiles to Targeted TherapiesSemantic proximity Read ↗

Clinicopathological Features, Tumor Mutational Burden, and Tumour-Infiltrating Lymphocyte Interplay in ERBB2-Mutated Breast Cancer: In Silico Analysis.Semantic proximity Read ↗

Clinicopathological features and prognosis of HER2 low-expression breast cancer: a single-center retrospective studySemantic proximity Read ↗

A gene expression-based classifier for HER2-low breast cancerSemantic proximity Read ↗

Molecular and clinical traits of HER2-low breast cancer patients and their relationship with neoadjuvant treatment effectiveness.Semantic proximity Read ↗

ERBB2 mutation frequency in lobular breast cancer with pleomorphic histology or high‐risk characteristics by molecular expression profilingSemantic proximity Read ↗

Secondary Transcriptomic Analysis of Triple Negative Breast Cancer Reveals Reliable Universal and Subtype-Specific BiomarkersSemantic proximity Read ↗

Clinical Genetic Features and Neoadjuvant Chemotherapy Response in HER2-Low Breast Cancers: A Retrospective, Multicenter Cohort Study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.